Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC25A | P30304 | 3/20 | 0.47 |
| ▸ | CDC25B | P30305 | 2/20 | 0.47 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.31 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.30 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.30 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4175826 | 0.82 | CDC25A (0.35) | CDC25ACDC25B | |
| SCHEMBL4175828 | 0.82 | CDC25A (0.35) | CDC25ACDC25B | |
| SCHEMBL4165167 | 0.76 | CYP19A1 (0.35) | CDC25ACDC25B | |
| SCHEMBL10041378 | 0.75 | CDC25A (0.51) | CDC25ACDC25BNR1H4GRIN2AGPBAR1 | |
| SCHEMBL15493923 | 0.75 | CDC25A (0.51) | CDC25ACDC25BNR1H4GRIN2AGPBAR1 | |
| SCHEMBL10041380 | 0.75 | CDC25A (0.51) | CDC25ACDC25BNR1H4GRIN2AGPBAR1 | |
| SCHEMBL10041382 | 0.75 | CDC25A (0.51) | CDC25ACDC25BNR1H4GRIN2AGPBAR1 | |
| SCHEMBL19263951 | 0.72 | CDC25A (0.55) | CDC25ACDC25BNR1H4GRIN2AGPBAR1 | |
| SCHEMBL10041381 | 0.72 | CDC25A (0.55) | CDC25ACDC25BNR1H4GRIN2AGPBAR1 | |
| SCHEMBL19263947 | 0.72 | CDC25A (0.55) | CDC25ACDC25BNR1H4GRIN2AGPBAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8377913-B2 | Vitamin D receptor activators and methods of making | ABBVIE INC. (US) | 2013-02-19 | — | — | US | disclosed |
| EP-2222635-A2 | NEW VITAMIN D RECEPTOR ACTIVATORS AND METHODS OF MAKING | Abbott Laboratories (US) | 2010-09-01 | — | — | EP | disclosed |
| WO-2009067578-A2 | NEW VITAMIN D RECEPTOR ACTIVATORS AND METHODS OF MAKING | ABBOTT LABORATORIES (US) | 2009-05-28 | — | — | WO | disclosed |
| US-20090131379-A1 | VITAMIN D RECEPTOR ACTIVATORS AND METHODS OF MAKING | ABBOTT LABORATORIES (US) | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131379-A1 | VITAMIN D RECEPTOR ACTIVATORS AND METHODS OF MAKING | VDR, CYP2R1, CYP24A1 | CDC25A 2827/4885CDC25B 3469/4885P2RY12 522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.